{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T04:36:25Z","timestamp":1784003785851,"version":"3.55.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["transplantationreviews.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation Reviews"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.trre.2016.10.004","type":"journal-article","created":{"date-parts":[[2016,10,12]],"date-time":"2016-10-12T20:10:03Z","timestamp":1476303003000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Acute antibody-mediated rejection in kidney transplant recipients"],"prefix":"10.1016","volume":"31","author":[{"given":"Scott","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.trre.2016.10.004_bb0005","doi-asserted-by":"crossref","first-page":"193724","DOI":"10.1155\/2012\/193724","article-title":"Antibody-mediated rejection in kidney transplantation: a review","volume":"2012","author":"Puttarajappa","year":"2012","journal-title":"J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0010","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/ajt.12982","article-title":"Quantifying renal allograft loss following early antibody-mediated rejection","volume":"15","author":"Orandi","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/nrneph.2010.34","article-title":"Sensitized renal transplant recipients: current protocols and future directions","volume":"6","author":"Gloor","year":"2010","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0020","doi-asserted-by":"crossref","first-page":"922","DOI":"10.2215\/CJN.08140910","article-title":"Desensitization protocols and their outcome","volume":"6","author":"Marfo","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0025","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1111\/j.1600-6143.2006.01416.x","article-title":"Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation","volume":"6","author":"Gloor","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0030","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1600-6143.2012.04291.x","article-title":"Five-year outcomes in living donor kidney transplants with a positive crossmatch","volume":"13","author":"Bentall","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0035","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1600-6143.2011.03840.x","article-title":"Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence","volume":"12","author":"Sellar\u00e9s","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0040","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.molmed.2015.02.004","article-title":"The perfect storm: HLA antibodies, complement, Fc\u03b3Rs, and endothelium in transplant rejection","volume":"21","author":"Thomas","year":"2015","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.trre.2016.10.004_bb0045","doi-asserted-by":"crossref","first-page":"3114","DOI":"10.1111\/ajt.12478","article-title":"Class II HLA epitope matching \u2013 a strategy to minimize de novo donor-specific antibody development and improve outcomes","volume":"13","author":"Wiebe","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0050","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1111\/ajt.13508","article-title":"Predicted indirectly recognizable HLA epitopes presented by HLA-DRB1 are related to HLA antibody formation during pregnancy","volume":"15","author":"Geneugelijk","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0055","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1016\/j.humimm.2013.07.001","article-title":"Moving beyond HLA: a review of nHLA antibodies in organ transplantation","volume":"74","author":"Sigdel","year":"2013","journal-title":"Hum Immunol"},{"key":"10.1016\/j.trre.2016.10.004_bb0060","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1111\/ajt.12397","article-title":"Pretransplant sensitization against angiotensin II type 1 receptor is a risk factor for acute rejection and graft loss","volume":"13","author":"Giral","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0065","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1111\/ajt.12395","article-title":"Higher risk of kidney graft failure in the presence of anti-angiotensin II type-1 receptor antibodies","volume":"13","author":"Taniguchi","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0070","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.transproceed.2014.09.029","article-title":"Non-HLA antibodies: angiotensin II type 1 receptor (anti-AT1R) and endothelin-1 type A receptor (anti-ETAR) are associated with renal allograft injury and graft loss","volume":"46","author":"Banasik","year":"2014","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.10.004_bb0075","doi-asserted-by":"crossref","first-page":"gfv375","DOI":"10.1093\/ndt\/gfv375","article-title":"The clinicopathological relevance of pretransplant anti-angiotensin II type 1 receptor antibodies in renal transplantation","author":"Lee","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0080","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/j.1600-6143.2006.01644.x","article-title":"Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival","volume":"7","author":"Terasaki","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0085","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1681\/ASN.2013121277","article-title":"Endothelial cell antibodies associated with novel targets and increased rejection","volume":"26","author":"Jackson","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0090","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/MOT.0000000000000216","article-title":"Effects of complement activation on allograft injury","volume":"20","author":"Sheen","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0095","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/TP.0b013e31827e6b45","article-title":"Endothelial injury in renal antibody-mediated allograft rejection: a schematic view based on pathogenesis","volume":"95","author":"Drachenberg","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0100","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1681\/ASN.2013121289","article-title":"Platelets in early antibody-mediated rejection of renal transplants","volume":"26","author":"Kuo","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0105","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.trim.2014.11.215","article-title":"Genes associated with antibody-dependent cell activation are overexpressed in renal biopsies from patients with antibody-mediated rejection","volume":"32","author":"Suviolahti","year":"2015","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2016.10.004_bb0110","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1111\/j.1600-6143.2010.03201.x","article-title":"NK cell transcripts and NK cells in kidney biopsies from patients with donor-specific antibodies: evidence for NK cell involvement in antibody-mediated rejection","volume":"10","author":"Hidalgo","year":"2010","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0115","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1111\/ajt.13115","article-title":"The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors","volume":"15","author":"Venner","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0120","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MOT.0000000000000193","article-title":"The molecular phenotypes of rejection in kidney transplant biopsies","volume":"20","author":"Halloran","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0125","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/TP.0000000000000757","article-title":"The role of natural killer cells in humoral rejection","volume":"99","author":"Resch","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0130","article-title":"Sialylation of antibodies in kidney recipients with de novo donor specific antibody, with or without antibody mediated rejection","author":"Malard-Castagnet","year":"2015","journal-title":"Hum Immunol"},{"key":"10.1016\/j.trre.2016.10.004_bb0135","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/MOT.0000000000000072","article-title":"An updated Banff schema for diagnosis of antibody-mediated rejection in renal allografts","volume":"19","author":"Haas","year":"2014","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0140","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/ajt.12807","article-title":"HLA antibody detection with solid phase assays: great expectations or expectations too great?","volume":"14","author":"Gebel","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0145","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.trim.2014.02.003","article-title":"Nothing's perfect: the art of defining HLA-specific antibodies","volume":"30","author":"Middleton","year":"2014","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2016.10.004_bb0150","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/ajt.12287","article-title":"Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA","volume":"13","author":"Reed","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0155","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1097\/TP.0000000000000229","article-title":"Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: prevalence, relevance, and impact on organ allocation","volume":"98","author":"Visentin","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0160","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1111\/ajt.13295","article-title":"Assessing antibody strength: comparison of MFI, C1q, and titer information","volume":"15","author":"Tambur","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0165","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/ki.1993.187","article-title":"Capillary deposition of C4d complement fragment and early renal graft loss","volume":"43","author":"Feucht","year":"1993","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2016.10.004_bb0170","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1034\/j.1600-6143.2003.00072.x","article-title":"Antibody-mediated rejection criteria \u2013 an addition to the Banff 97 classification of renal allograft rejection","volume":"3","author":"Racusen","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0175","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1111\/j.1600-6143.2011.03926.x","article-title":"Banff 2011 Meeting report: new concepts in antibody-mediated rejection","volume":"12","author":"Mengel","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0180","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1097\/MOT.0b013e3283352a50","article-title":"Endothelial transcripts uncover a previously unknown phenotype: C4d-negative antibody-mediated rejection","volume":"15","author":"Sis","year":"2010","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0185","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/j.1600-6143.2009.02761.x","article-title":"Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining","volume":"9","author":"Sis","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0190","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1600-6143.2010.03364.x","article-title":"Significance of C4d Banff scores in early protocol biopsies of kidney transplant recipients with preformed donor-specific antibodies (DSA)","volume":"11","author":"Loupy","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0195","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/ajt.12590","article-title":"Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions","volume":"14","author":"Haas","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0200","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/MNH.0b013e3283520efa","article-title":"Pathologic features of antibody-mediated rejection in renal allografts: an expanding spectrum","volume":"21","author":"Haas","year":"2012","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.trre.2016.10.004_bb0205","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(12)61265-3","article-title":"Antibody-mediated vascular rejection of kidney allografts: a population-based study","volume":"381","author":"Lefaucheur","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.trre.2016.10.004_bb0210","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1681\/ASN.2014111064","article-title":"Reassessing the significance of intimal arteritis in kidney transplant biopsy specimens","volume":"26","author":"Salazar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0215","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1681\/ASN.2013111149","article-title":"Molecular microscope strategy to improve risk stratification in early antibody-mediated kidney allograft rejection","volume":"25","author":"Loupy","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0220","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/ajt.12150","article-title":"Molecular diagnosis of antibody-mediated rejection in human kidney transplants","volume":"13","author":"Sellar\u00e9s","year":"2013","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0225","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.trre.2013.10.004","article-title":"Urine proteomics in kidney transplantation","volume":"28","author":"Kim","year":"2014","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2016.10.004_bb0230","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.trre.2014.12.003","article-title":"Genomic and proteomic fingerprints of acute rejection in peripheral blood and urine","volume":"29","author":"Ong","year":"2015","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2016.10.004_bb0235","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/ndt\/gfu280","article-title":"MicroRNAs in kidney transplantation","volume":"30","author":"Wilflingseder","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0240","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/TP.0b013e31829434d4","article-title":"Early versus late acute antibody-mediated rejection in renal transplant recipients","volume":"96","author":"D\u00f6rje","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0245","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1111\/ajt.12786","article-title":"Quantifying the risk of incompatible kidney transplantation: a multicenter study","volume":"14","author":"Orandi","year":"2014","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0250","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1681\/ASN.2009101065","article-title":"Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation","volume":"21","author":"Lefaucheur","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0255","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1097\/TP.0b013e3181f6a07b","article-title":"Pretransplant donor-specific antibodies detected by single-antigen bead flow cytometry are associated with inferior kidney transplant outcomes","volume":"90","author":"Singh","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0260","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.trim.2015.01.002","article-title":"Analysis of preformed donor-specific anti-HLA antibodies characteristics for prediction of antibody-mediated rejection in kidney transplantation","volume":"32","author":"Malheiro","year":"2015","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trre.2016.10.004_bb0265","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1097\/TP.0000000000000511","article-title":"Characteristics of circulating donor human leukocyte antigen-specific immunoglobulin G antibodies predictive of acute antibody-mediated rejection and kidney allograft failure","volume":"99","author":"Kannabhiran","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0270","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1600-6143.2005.01178.x","article-title":"A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody","volume":"6","author":"Stegall","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0275","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/j.1600-6143.2008.02441.x","article-title":"Alloantibody levels and acute humoral rejection early after positive crossmatch kidney transplantation","volume":"8","author":"Burns","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0280","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1097\/TP.0b013e3182139da1","article-title":"Inferior kidney allograft outcomes in patients with de novo donor-specific antibodies are due to acute rejection episodes","volume":"91","author":"Cooper","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0285","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/TP.0b013e3181c3503e","article-title":"Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection","volume":"89","author":"Gill","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0290","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1111\/j.1600-6143.2008.02428.x","article-title":"Posttransplant HLA alloreactivity in stable kidney transplant recipients-incidences and impact on long-term allograft outcomes","volume":"8","author":"Bartel","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0295","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1097\/01.TP.0000438196.30790.66","article-title":"Intermediate-term graft loss after renal transplantation is associated with both donor-specific antibody and acute rejection","volume":"97","author":"DeVos","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0300","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/ajt.13347","article-title":"Rates and determinants of progression to graft failure in kidney allograft recipients with de novo donor-specific antibody","volume":"15","author":"Wiebe","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0305","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-6143.2009.02577.x","article-title":"Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss","volume":"9","author":"Everly","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0310","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1097\/TP.0b013e3181cbac02","article-title":"Beyond histology: lowering human leukocyte antigen antibody to improve renal allograft survival in acute rejection","volume":"89","author":"Everly","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0315","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1056\/NEJMoa1302506","article-title":"Complement-binding anti-HLA antibodies and kidney-allograft survival","volume":"369","author":"Loupy","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trre.2016.10.004_bb0320","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/TP.0b013e3182743cfa","article-title":"Preformed complement-activating low-level donor-specific antibody predicts early antibody-mediated rejection in renal allografts","volume":"95","author":"Lawrence","year":"2013","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0325","article-title":"IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury","author":"Lefaucheur","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0330","first-page":"1","article-title":"Non-complement-binding de novo donor-specific anti-HLA antibodies and kidney allograft survival","author":"Guidicelli","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0335","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1097\/TP.0000000000000699","article-title":"C1q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection","volume":"99","author":"Yell","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0340","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1681\/ASN.V131234","article-title":"C4d deposition in acute rejection: an independent long-term prognostic factor","volume":"13","author":"Herzenberg","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0345","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1046\/j.1523-1755.2001.00495.x","article-title":"Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts","volume":"59","author":"Lederer","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.trre.2016.10.004_bb0350","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1111\/j.1600-6143.2009.02836.x","article-title":"The impact of c4d pattern and donor-specific antibody on graft survival in recipients requiring indication renal allograft biopsy","volume":"9","author":"Haririan","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0355","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/j.1600-6143.2009.02555.x","article-title":"Focal C4d+ in renal allografts is associated with the presence of donor-specific antibodies and decreased allograft survival","volume":"9","author":"Kedainis","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0360","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/ajt.13434","article-title":"Presentation and outcomes of C4d-negative antibody-mediated rejection after kidney transplantation","volume":"16","author":"Orandi","year":"2015","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0365","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2215\/CJN.09901014","article-title":"Capillary C4d and kidney allograft outcome in relation to morphologic lesions suggestive of antibody-mediated rejection","volume":"10","author":"Kiki\u0107","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.trre.2016.10.004_bb0370","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1097\/TP.0b013e31825d1587","article-title":"The treatment of acute antibody-mediated rejection in kidney transplant recipients \u2013 a systematic review","volume":"94","author":"Roberts","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0375","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1111\/j.1600-6143.2011.03525.x","article-title":"Summary of FDA antibody-mediated rejection workshop","volume":"11","author":"Archdeacon","year":"2011","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0380","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/ctr.12491","article-title":"Treatment of antibody-mediated rejection in renal transplant patients: a clinical practice survey","volume":"29","author":"Burton","year":"2015","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2016.10.004_bb0385","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1097\/MOT.0000000000000250","article-title":"Intravenous immunoglobulin in kidney transplantation","volume":"20","author":"Tedla","year":"2015","journal-title":"Curr Opin Organ Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0390","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.tp.0000261113.30757.d1","article-title":"Rituximab therapy for acute humoral rejection after kidney transplantation","volume":"83","author":"Faguer","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0395","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1097\/TP.0b013e31819389cc","article-title":"A single low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection","volume":"87","author":"Mulley","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0400","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1600-6143.2004.00454.x","article-title":"Rituximab as treatment for refractory kidney transplant rejection","volume":"4","author":"Becker","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0405","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1399-0012.2008.00902.x","article-title":"Impact of rituximab therapy for treatment of acute humoral rejection","volume":"23","author":"Kaposztas","year":"2009","journal-title":"Clin Transpl"},{"key":"10.1016\/j.trre.2016.10.004_bb0410","doi-asserted-by":"crossref","first-page":"3393","DOI":"10.1016\/j.transproceed.2008.08.131","article-title":"High-dose intravenous immunoglobulin and rituximab treatment for antibody-mediated rejection after kidney transplantation: a cost analysis","volume":"40","author":"Tanriover","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.10.004_bb0415","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1111\/j.1600-6143.2008.02411.x","article-title":"A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation","volume":"8","author":"Zarkhin","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0420","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1111\/j.1600-6143.2009.02591.x","article-title":"Comparison of combination Plasmapheresis\/IVIg\/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection","volume":"9","author":"Lefaucheur","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0425","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1097\/TP.0000000000000958","article-title":"One-year results of the effects of rituximab on acute antibody-mediated rejection in renal transplantation: RITUX ERAH, a multicenter double-blind randomized placebo-controlled trial","volume":"100","author":"Sautenet","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0430","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1097\/TP.0b013e318190af83","article-title":"Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection","volume":"86","author":"Everly","year":"2008","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0435","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/TP.0b013e3181c6ff8d","article-title":"Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection","volume":"89","author":"Walsh","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0440","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/TP.0b013e318218e901","article-title":"Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition","volume":"91","author":"Walsh","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0445","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1097\/TP.0b013e3181fdd9b0","article-title":"The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation","volume":"90","author":"Flechner","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0450","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/petr.12274","article-title":"Efficacy of bortezomib for reducing donor-specific antibodies in children and adolescents on a steroid minimization regimen","volume":"18","author":"Nguyen","year":"2014","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0455","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/j.1600-6143.2008.02451.x","article-title":"The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection","volume":"9","author":"Locke","year":"2009","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0460","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1111\/j.1600-6143.2012.04124.x","article-title":"Antibody mediated rejection associated with complement factor h-related protein 3\/1 deficiency successfully treated with eculizumab","volume":"12","author":"Noone","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0465","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1016\/j.transproceed.2012.03.053","article-title":"Case report: eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant","volume":"44","author":"Stewart","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.10.004_bb0470","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.transproceed.2013.02.062","article-title":"Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports","volume":"45","author":"Kocak","year":"2013","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trre.2016.10.004_bb0475","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/petr.12187","article-title":"Plasmapheresis-resistant acute humoral rejection successfully treated with anti-C5 antibody","volume":"18","author":"Ghirardo","year":"2014","journal-title":"Pediatr Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0480","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1097\/TP.0000000000000298","article-title":"Eculizumab and splenectomy as salvage therapy for severe antibody-mediated rejection after HLA-incompatible kidney transplantation","volume":"98","author":"Orandi","year":"2014","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0485","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1432-2277.2012.01490.x","article-title":"Prevention of antibody-mediated kidney transplant rejection","volume":"25","author":"Morath","year":"2012","journal-title":"Transpl Int"},{"key":"10.1016\/j.trre.2016.10.004_bb0490","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/TP.0b013e3181a9ec89","article-title":"A lifetime versus a graft life approach redefines the importance of HLA matching in kidney transplant patients","volume":"88","author":"Meier-Kriesche","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.trre.2016.10.004_bb0495","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1093\/ndt\/gfu309","article-title":"Kidney paired donation: principles, protocols and programs","volume":"30","author":"Ferrari","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0500","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1600-6143.2012.04013.x","article-title":"Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant","volume":"12","author":"Wiebe","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trre.2016.10.004_bb0505","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.trre.2014.10.001","article-title":"Monitoring drug adherence","volume":"29","author":"Lieber","year":"2015","journal-title":"Transplant Rev (Orlando)"},{"key":"10.1016\/j.trre.2016.10.004_bb0510","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1093\/ndt\/gfu204","article-title":"Interventions to improve medication adherence in adult kidney transplant recipients: a systematic review","volume":"30","author":"Low","year":"2015","journal-title":"Nephrol Dial Transplant"}],"container-title":["Transplantation Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X1630012X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0955470X1630012X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,10]],"date-time":"2022-07-10T06:33:46Z","timestamp":1657434826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0955470X1630012X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":102,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0955470X1630012X"],"URL":"https:\/\/doi.org\/10.1016\/j.trre.2016.10.004","relation":{},"ISSN":["0955-470X"],"issn-type":[{"value":"0955-470X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute antibody-mediated rejection in kidney transplant recipients","name":"articletitle","label":"Article Title"},{"value":"Transplantation Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trre.2016.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}